Venus Remedies successfully obtains 3 new Marketing Authorizations for Enoxaparin from Bahrain

Venus Remedies Limited has successfully obtained three new Marketing Authorizations for Enoxaparin, a critical anticoagulant medication. The approved formulations include Enoxaparin 80mg/0.8ml, 60mg/0.6ml, and 20mg/0.2ml. The approvals have been granted by the regulatory authorities in Bahrain, strategically positioning us for growth in the Asia (Middle East) region.

Shares of Venus Remedies Limited was last trading in BSE at Rs. 384.00 as compared to the previous close of Rs. 378.95. The total number of shares traded during the day was 4907 in over 477 trades.

The stock hit an intraday high of Rs. 385.75 and intraday low of 371.40. The net turnover during the day was Rs. 1863855.00.

Source : Equity Bulls

Keywords

VenusRemedies INE411B01019 Three MarketAuthorizations Enoxaparin CriticalAnticoagulantMedication Bahrain